SMARCA4-deficient non-small cell carcinoma of the lung

From Libre Pathology
Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

SMARCA4-deficient non-small cell carcinoma of the lung is an emerging subtype of lung cancer.[1]

General

  • ~5.1% of non-small cell carcinoma is SMARCA4 deficient in a series of 316 cases.[2]
  • May represent or overlap with what is known as hepatoid adenocarcinoma of the lung.[citation needed]
  • The main differential diagnosis is metastatic adenocarcinoma.

IHC

Features:[1]

  • CK7 +ve.
  • TTF-1 -ve.
  • HepPar-1 +ve (15/20 +ve, 2/20 isolated +ve cells, 3/20 -ve).[1]
  • SMARCA4 -ve.
  • Napsin A -ve (1/28 +ve).[3]

Note:

Sign out

The tumour stains as follows: 
POSITIVE: CK7 (diffuse, strong), HepPar-1 (strong, diffuse).
NEGATIVE: TTF-1, napsin A, p63, CK5/6.

The staining pattern for this tumour is not typical for lung adenocarcinoma; please correlate with the clinical findings.

HepPar-1 POSITIVITY with CK7 POSITIVITY and TTF-1 NEGATIVITY may be seen in SMARCA4-deficient adenocarcinoma of the lung.[1]

1. Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.

See also

References

  1. ↑ 1.0 1.1 1.2 Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.
  2. ↑ Herpel, E.; Rieker, RJ.; Dienemann, H.; Muley, T.; Meister, M.; Hartmann, A.; Warth, A.; Agaimy, A. (Feb 2017). "SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.". Ann Diagn Pathol 26: 47-51. doi:10.1016/j.anndiagpath.2016.10.006. PMID 28038711.
  3. ↑ Sayeda S, Naqvi A, Begum H, Finley C, Coschi C, Juergens R, Bonert M. (August 2022). "34th European Congress of Pathology - Abstracts (Prevalence of TTF-1 negative lung adenocarcinoma on lung core biopsy with EGFR, ALK and PD-L1 status)". Virchows Arch 481 (Suppl 1): 1–364. doi:10.1007/s00428-022-03379-4. PMC 9379246. PMID 35972647. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379246/.
  4. ↑ Haninger, DM.; Kloecker, GH.; Bousamra Ii, M.; Nowacki, MR.; Slone, SP. (Apr 2014). "Hepatoid adenocarcinoma of the lung: report of five cases and review of the literature.". Mod Pathol 27 (4): 535-42. doi:10.1038/modpathol.2013.170. PMID 24030743.
Retrieved from "https://librepathology.org/w/index.php?title=SMARCA4-deficient_non-small_cell_carcinoma_of_the_lung&oldid=52472"